Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
AMDS PERSEVERE Trial Results: The AMDS PERSEVERE trial showed that 83% of patients with visceral malperfusion and 74% with renal malperfusion experienced resolution of their conditions within 30 days post-implantation of the AMDS Hybrid Prosthesis.
Validation from AMDS PROTECT Trial: Real-world data from the AMDS PROTECT trial confirmed the positive outcomes observed in the PERSEVERE trial, demonstrating low rates of complications such as disabling stroke and renal failure requiring dialysis among patients treated with the AMDS.
Trade with 70% Backtested Accuracy
Analyst Views on AORT
About AORT
About the author
Artivion, Inc. Reports Strong Q4 2025 Earnings Growth
- Significant Revenue Growth: Artivion reported adjusted revenues of $118.3 million for Q4 2025, an 18.5% increase year-over-year, with stent graft revenues up 36% and On-X revenues up 24%, indicating strong market demand in the cardiovascular sector.
- Outstanding EBITDA Performance: Adjusted EBITDA for the fourth quarter increased approximately 29%, rising from $17.6 million to $22.7 million, with an EBITDA margin improvement to 19.2%, reflecting ongoing enhancements in cost control and operational efficiency.
- Clinical Trial Progress: The AMDS PERSEVERE and NEXUS TRIOMPHE trials reported a 94% patient survival rate and 91% free from stroke at one year, setting the stage for potential approval in the second half of 2026, which will further drive market expansion.
- Optimistic Future Outlook: Artivion projects revenue growth of 10% to 14% for 2026, targeting a revenue range of $486 million to $504 million, with management expressing confidence in sustained double-digit revenue growth and EBITDA margin expansion, emphasizing the strategic use of its differentiated product portfolio to seize market opportunities.
Artivion (AORT) Q4 2025 Earnings Call Transcript
Artivion Reports Strong 2025 Earnings, Outlook for Growth in 2026
- Significant Revenue Growth: Artivion reported total adjusted revenues of $443.6 million for 2025, reflecting a 13% year-over-year increase, with Q4 revenue reaching $118.3 million, up 18.5% from 2024, indicating strong market performance and sustained customer demand.
- Substantial EBITDA Improvement: The adjusted EBITDA for 2025 grew by 26% to $102.7 million, with an EBITDA margin of 20.2%, showcasing the company's significant progress in cost control and operational efficiency, thereby enhancing future profitability.
- Strong Product Line Performance: In Q4, stent graft revenues surged by 36% year-over-year, while On-X heart valve revenues increased by 24%, reflecting Artivion's expanding market share in key product areas, particularly driven by robust demand in both the U.S. and international markets.
- Clinical Data Supporting Future Growth: Positive clinical trial results for Artivion's AMDS and NEXUS product lines are expected to drive further growth in 2026, with the AMDS market opportunity projected at $150 million and NEXUS at $150 million, highlighting the company's strong potential in innovative medical technologies.
HOLX's Innovative AI Mammography Identifies Overlooked Breast Cancer Cases
Clinical Evidence of AI Effectiveness: Hologic, Inc. announced that its Genius AI-based mammography technology significantly improves breast cancer detection, identifying 32% of previously missed cases in a study involving 7,500 exams.
Market Impact and Growth Prospects: Despite a slight decline in shares following the announcement, Hologic's advancements in AI technology are expected to drive long-term growth in the breast health segment, with a market capitalization of $16.76 billion.
AI's Role in Cancer Detection: The AI tool demonstrated high accuracy in localizing suspicious cancer areas, enhancing diagnostic confidence, particularly for invasive ductal cancers, while acknowledging limitations in identifying certain cancer types.
Future Developments and Market Trends: Hologic plans to present new clinical data at an upcoming conference, and the breast cancer diagnostics market is projected to grow significantly, driven by increased awareness and technological innovations.
Artivion Insider Offloads Shares Valued at $576,502, Per Recent SEC Disclosure
Sale of Shares: Jean F Holloway, Senior Vice President and General Counsel, sold 12,787 shares on November 14, 2025.
Portfolio Access: Users need to sign in to access their portfolio information.
Artivion Insider Offloads Shares Valued at $264,188, Based on Recent SEC Disclosure
Stock Sale: Jean F Holloway, Senior Vice President and General Counsel, sold 5,761 shares on November 13, 2025.
Portfolio Access: Users need to sign in to access their portfolio information.
Artivion, Inc. Reports Strong Q4 2025 Earnings Growth
- Significant Revenue Growth: Artivion reported adjusted revenues of $118.3 million for Q4 2025, an 18.5% increase year-over-year, with stent graft revenues up 36% and On-X revenues up 24%, indicating strong market demand in the cardiovascular sector.
- Outstanding EBITDA Performance: Adjusted EBITDA for the fourth quarter increased approximately 29%, rising from $17.6 million to $22.7 million, with an EBITDA margin improvement to 19.2%, reflecting ongoing enhancements in cost control and operational efficiency.
- Clinical Trial Progress: The AMDS PERSEVERE and NEXUS TRIOMPHE trials reported a 94% patient survival rate and 91% free from stroke at one year, setting the stage for potential approval in the second half of 2026, which will further drive market expansion.
- Optimistic Future Outlook: Artivion projects revenue growth of 10% to 14% for 2026, targeting a revenue range of $486 million to $504 million, with management expressing confidence in sustained double-digit revenue growth and EBITDA margin expansion, emphasizing the strategic use of its differentiated product portfolio to seize market opportunities.
Artivion (AORT) Q4 2025 Earnings Call Transcript
Artivion Reports Strong 2025 Earnings, Outlook for Growth in 2026
- Significant Revenue Growth: Artivion reported total adjusted revenues of $443.6 million for 2025, reflecting a 13% year-over-year increase, with Q4 revenue reaching $118.3 million, up 18.5% from 2024, indicating strong market performance and sustained customer demand.
- Substantial EBITDA Improvement: The adjusted EBITDA for 2025 grew by 26% to $102.7 million, with an EBITDA margin of 20.2%, showcasing the company's significant progress in cost control and operational efficiency, thereby enhancing future profitability.
- Strong Product Line Performance: In Q4, stent graft revenues surged by 36% year-over-year, while On-X heart valve revenues increased by 24%, reflecting Artivion's expanding market share in key product areas, particularly driven by robust demand in both the U.S. and international markets.
- Clinical Data Supporting Future Growth: Positive clinical trial results for Artivion's AMDS and NEXUS product lines are expected to drive further growth in 2026, with the AMDS market opportunity projected at $150 million and NEXUS at $150 million, highlighting the company's strong potential in innovative medical technologies.
HOLX's Innovative AI Mammography Identifies Overlooked Breast Cancer Cases
Clinical Evidence of AI Effectiveness: Hologic, Inc. announced that its Genius AI-based mammography technology significantly improves breast cancer detection, identifying 32% of previously missed cases in a study involving 7,500 exams.
Market Impact and Growth Prospects: Despite a slight decline in shares following the announcement, Hologic's advancements in AI technology are expected to drive long-term growth in the breast health segment, with a market capitalization of $16.76 billion.
AI's Role in Cancer Detection: The AI tool demonstrated high accuracy in localizing suspicious cancer areas, enhancing diagnostic confidence, particularly for invasive ductal cancers, while acknowledging limitations in identifying certain cancer types.
Future Developments and Market Trends: Hologic plans to present new clinical data at an upcoming conference, and the breast cancer diagnostics market is projected to grow significantly, driven by increased awareness and technological innovations.
Artivion Insider Offloads Shares Valued at $576,502, Per Recent SEC Disclosure
Sale of Shares: Jean F Holloway, Senior Vice President and General Counsel, sold 12,787 shares on November 14, 2025.
Portfolio Access: Users need to sign in to access their portfolio information.
Artivion Insider Offloads Shares Valued at $264,188, Based on Recent SEC Disclosure
Stock Sale: Jean F Holloway, Senior Vice President and General Counsel, sold 5,761 shares on November 13, 2025.
Portfolio Access: Users need to sign in to access their portfolio information.
